HIV lipodystrophy syndrome: a primer.
Treatment with highly active antiretroviral therapy (HAART) has been implicated in the development of anthropomorphic and metabolic abnormalities termed HIV lipodystrophy syndrome (or LDS). This primer offers a comprehensive overview of LDS including epidemiology, hypothesized etiologies, and clinical consequences. The evidence-based literature is reviewed for current treatment strategies including discontinuation of specific antiretrovirals, pharmacological management of dyslipidemia and insulin resistance, exercise training, facial augmentation, liposuction, and hormonal therapy. Patient education, counseling, and adherence are discussed.
College of Nursing, University of Illinois at Chicago, USA.
F Patrick
FP
Robinson
D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D001828:Body Image; D019317:Evidence-Based Medicine; D005081:Exercise Therapy; D039682:HIV-Associated Lipodystrophy Syndrome / Q000453:epidemiology / Q000209:etiology / Q000378:metabolism / Q000523:psychology / Q000628:therapy; D006801:Humans; D007333:Insulin Resistance; D024802:Nurse's Role; D010349:Patient Compliance; D010353:Patient Education as Topic; D015995:Prevalence; D011788:Quality of Life; D012307:Risk Factors; D016896:Treatment Outcome